18:11 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Osteoarthritis Patient sample and mouse studies suggest promoting senescent cell clearance could help treat osteoarthritis (OA). In patient-derived cultured human cartilage, a compound that induces apoptosis in senescent cells (UBX0101) increased proliferation of healthy chondrocytes...
07:00 , Apr 14, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Matrix metalloproteinase 13 (MMP13)

Musculoskeletal disease INDICATION: Musculoskeletal Patient sample and mouse studies suggest inhibiting MMP13 could help treat bone loss in multiple myeloma (MM). In MM cells from patient bone marrow, MMP13 levels were higher than in bone marrow...
07:00 , Oct 23, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Osteoarthritis Matrix metalloproteinase 13 (MMP13) In vitro and rat studies identified selective MMP13 inhibitors that...
07:00 , Jun 28, 2012 |  BC Innovations  |  Strategy

Pharma compounds at the crossroads

The National Center for Advancing Translational Sciences (NCATS) has disclosed details about the first library of therapeutics in its Discovering New Therapeutic Uses for Existing Molecules program (see "Repurposing pharma compounds"). The compounds provided...
08:00 , Dec 8, 2011 |  BC Innovations  |  Cover Story

Big MAC attack in osteoarthritis

An international research team has shown that inhibiting the complement system slows disease progression in mice with osteoarthritis, thus pointing to complement inhibitors as potential disease modifiers.1 Although the findings offer companies developing inhibitors of...
07:00 , Sep 2, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Lung cancer; prostate cancer; breast cancer; congestive heart failure (CHF) Matrix metalloproteinase 2 (MMP2); MMP9; MMP13 In...
07:00 , Jun 3, 2010 |  BC Innovations  |  Cover Story

HIF2A: mastering osteoarthritis

Most approved osteoarthritis therapies treat symptoms of the disease but not the underlying processes that lead to cartilage destruction and bone spur formation in joints. Now, separate research teams from Japan and South Korea have...
07:00 , Aug 6, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Osteoarthritis Matrix metalloproteinase...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease ...
08:00 , Feb 28, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease ...